The role of insulin-like growth factor-1 and growth hormone in the mortality of patients with acromegaly after trans-sphenoidal surgery

Growth Hormone and IGF Research

Volumn 20, Issue 6, 2010, Pages 411-415

  Wu, Tzu En ^b,c   Lin, Hong Da ^a,b   Lu, Ron A ^a   Wang, Mei Li ^a   Chen, Ru Lin ^a   Chen, Harn Shen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Acromegaly; Growth hormone; IGF 1; Mortality

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; TAIWAN; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION;

ACROMEGALY; ADULT; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SPHENOID BONE; SURGICAL PROCEDURES, OPERATIVE; SURVIVAL ANALYSIS;

EID: 78649630661     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2010.09.003     Document Type: Article

References (21)

1. Melmed S. Medical progress: acromegaly. N Engl J. Med. 2006, 355:2558-2573.
2. Alexander L., Appleton D., Hall R., Ross W.M., Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin. Endocrinol. 1980, 12:71-79.
3. Holdaway I.M., Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999, 2:29-41.
4. Kauppinen-Makelin R., Sane T., Reunanen A., et al. A nationwide survey of mortality in acromegaly. J. Clin. Endocrinol. Metab. 2005, 90:4081-4086.
5. Nabarro J.D.N. Acromegaly. Clin. Endocrinol. 1987, 26:481-512.
6. Orme S.M., McNally R.J., Cartwright R.A., Belchetz P.E. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J. Clin. Endocrinol. Metab. 1998, 83:2730-2734.
7. Dekkers O.M., Biermasz N.R., Pereira A.M., Romijn J.A., Vandenbroucke J.P. Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 2008, 93:61-67.
8. Holdaway I.M., Bolland M.J., Gamble G.D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 2008, 159:89-95.
9. Ayuk J., Clayton R.N., Holder G., et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor I concentrations predict excess mortality in patients with acromegaly. J. Clin. Endocrinol. Metab. 2004, 89:1613-1617.
10. Biermasz N.R., Dekker F.W., Pereira A.M., et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J. Clin. Endocrinol. Metab. 2004, 89:2789-2796.
11. Holdaway I.M., Rajasoorya R.C., Gamble G.D. Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 2004, 89:667-674.
12. Giustina A., Barkan A., Casanueva F.F., et al. Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 2000, 85:526-529.
13. Consensus statement. Biochemical assessment and long-term monitoring in patients with acromegaly: Statement from a Joint Consensus Conference of The Growth Hormone Research Society and The Pituitary Society. J. Clin. Endocrinol. Metab. 2004, 89:3099-4102.
14. Abosch A., Tyrrell J.B., Lamborn K.R., et al. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J. Clin. Endocrinol. Metab. 1998, 83:3411-3418.
15. Swearingen B., Barker F.G., Katznelson L., et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. 1998, 83:3419-3426.
16. Biermasz N.R., van Dulken H., Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J. Clin. Endocrinol. Metab. 2000, 85:4596-4602.
17. Freda P.U. How effective are current therapies for acromegaly?. Growth Horm. IGF Res. 2003, 13(Suppl A):S144-S151.
18. Clemmons D.R., Strasburger C. Monitoring the response to treatment in acromegaly. J. Clin. Endocrinol. Metab. 2004, 89:5289-5291.
19. Bates A.S., Van't Hoff W., Jones J.M., Clayton R.N. An audit of outcome of treatment in acromegaly. QJM-An Intern. J. Med. 1993, 86:293-299.
20. Ayuk J., Stewart S.E., Stewart P.M., Sheppard M.C. Efficacy of sandostatin LAR (long acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin. Endocrinol. 2004, 60:375-381. European Sandostatin LAR Group.
21. Alexopoulou O., Bex M., Abs R., et al. Divergence between growth hormone and insulin-like growth factor-1 concentrations in the follow-up of acromegaly. J. Clin. Endocrinol. Metab. 2008, 93:1324-1330.